HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acetazolamide: a treatment for chronic mountain sickness.

AbstractRATIONALE:
Chronic mountain sickness or Monge's disease is characterized by an excessive polycythemia in high-altitude dwellers, with a prevalence of 5 to 18% above 3,200 m. To date, no pharmacologic treatment is available.
OBJECTIVES:
We evaluated the efficacy of acetazolamide in the treatment of chronic mountain sickness and the importance of nocturnal hypoxemia in its pathophysiology.
METHODS:
A double-blind placebo-controlled study was performed in three groups of patients from Cerro de Pasco, Peru (4,300 m), treated orally for 3 weeks with placebo (n = 10), 250 mg of acetazolamide (n = 10), or 500 mg of acetazolamide (n = 10), daily.
RESULTS:
Acetazolamide decreased hematocrit by 7.1% (p < 0.001) and 6.7% (p < 0.001), serum erythropoietin by 67% (p < 0.01) and 50% (p < 0.001), and serum soluble transferrin receptors by 11.1% (p < 0.05) and 3.4% (p < 0.001), and increased serum ferritin by 540% (p < 0.001) and 134% (p < 0.001), for groups treated with 250 and 500 mg of acetazolamide, respectively. Acetazolamide (250 mg) increased nocturnal arterial O(2) saturation by 5% (p < 0.01) and decreased mean nocturnal heart rate by 11% (p < 0.05) and the number of apnea-hypopnea episodes during sleep by 74% (p < 0.05). The decrease in erythropoietin was attributed mainly to the acetazolamide-induced increase in ventilation and arterial O(2) saturation.
CONCLUSIONS:
Acetazolamide, the first efficient pharmacologic treatment of chronic mountain sickness without adverse effects, reduces hypoventilation, which may be accentuated during sleep, and blunts erythropoiesis. Its low cost may allow wide development with a considerable positive impact on public health in high-altitude regions.
AuthorsJean-Paul Richalet, Maria Rivera, Patrick Bouchet, Eduardo Chirinos, Igor Onnen, Olivier Petitjean, Annick Bienvenu, Francçoise Lasne, Stéphane Moutereau, Fabiola León-Velarde
JournalAmerican journal of respiratory and critical care medicine (Am J Respir Crit Care Med) Vol. 172 Issue 11 Pg. 1427-33 (Dec 01 2005) ISSN: 1073-449X [Print] United States
PMID16126936 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Carbonic Anhydrase Inhibitors
  • Erythropoietin
  • Acetazolamide
Topics
  • Acetazolamide (administration & dosage, therapeutic use)
  • Administration, Oral
  • Adult
  • Altitude Sickness (blood, drug therapy, physiopathology)
  • Blood Pressure (drug effects)
  • Carbonic Anhydrase Inhibitors (administration & dosage, therapeutic use)
  • Chronic Disease
  • Circadian Rhythm (physiology)
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Electrocardiography
  • Erythropoietin (blood)
  • Follow-Up Studies
  • Heart Rate (drug effects)
  • Hematocrit
  • Humans
  • Male
  • Oximetry
  • Oxygen Consumption (drug effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: